Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891243 | PMC |
| http://dx.doi.org/10.1093/rap/rkad012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 and cardiovascular complications: updates of emergency medicine.
Emerg Crit Care Med
September 2023
Emergency Medicine Department, Thomas Jefferson University, Philadelphia, PA, USA.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV-2 variants, has become a global pandemic resulting in significant morbidity and mortality. Severe cases of COVID-19 are characterized by hypoxemia, hyper-inflammation, cytokine storm in lung. Clinical studies have reported an association between COVID-19 and cardiovascular disease (CVD).
View Article and Find Full Text PDFRenal artery infarction in the SARS-Cov-2 era: A systematic review of case reports.
Arch Ital Urol Androl
October 2023
Konstantopouleio General Hospital of Nea Ionia, Department of Urology, Nea Ionia, Attiki.
Aim: Renal artery infarction (RI) is the presence of blood clot in the main renal artery or its branches causing complete or partial obstruction of the blood supply. Its etiology is either related with disorders of the renal vasculature or with cardiovascular diseases. Recently, the SARSCoV- 2 virus is an emerging cause of thromboembolic events and the incidence of RI is anticipated to increase after the pandemic.
View Article and Find Full Text PDFHealing Treatments in COVID-19 Patients: A Narrative Review.
J Clin Med
July 2023
Infectious Diseases Department, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
Since December 2019, many drugs have been evaluated or advocated as potential treatments of SARS-CoV-2 induced disease (COVID-19), including many repositioned drugs and some others specifically developed for these diseases. They can be roughly classified into three categories according to their main mechanism of action (passive immunization, direct antivirals, and anti-inflammatory treatments), and their use depends on the stage of the disease. Despite often promising preclinical data, most of the treatments evaluated failed to show a significant clinical benefit.
View Article and Find Full Text PDFSARS-CoV-2-induced venous thromboembolism in a patient with VEXAS syndrome.
Rheumatol Adv Pract
January 2023
General Medicine Unit, Girolamo Fracastoro Hospital, AULSS9 Scaligera, San Bonifacio, Verona, Italy.
Case Report: Successful Treatment of a Child With COVID-19 Reinfection-Induced Fulminant Myocarditis by Cytokine-Adsorbing ® Hemofilter Continuous Veno-Venous Hemofiltration and Extracorporeal Membrane Oxygenation.
Front Pediatr
July 2022
Pediatric COVID-19 Intensive Care Unit, Vietnam National Children's Hospital, Hanoi, Vietnam.
Background: Indirect cardiomyocyte damage-related hyperinflammatory response is one of the key mechanisms in COVID-19-induced fulminant myocarditis. In addition to the clinical benefit of using cytokines absorption hemofiltration, the effectiveness of instituting veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support for cardiac compromise has been reported. However, current literature enunciates a paucity of available data on the effectiveness of these novel modalities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!